Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oxford BioMedica ( (GB:OXB) ) has shared an announcement.
Oxford Biomedica has successfully completed a placing of new ordinary shares, raising approximately £60 million. The funds will be used to expand its US commercial-scale capacity and improve process quality, addressing growing client demand across clinical phases. The placing was well-supported by both new and existing shareholders, and the shares are expected to be admitted to trading on the London Stock Exchange by 20 August 2025.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
Oxford BioMedica’s overall stock score reflects strong technical indicators and positive corporate events, which are offset by financial instability and valuation concerns. The earnings call provided a positive outlook, but the company’s high leverage and negative profitability remain significant risks.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica plc is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, the company provides viral vector development and manufacturing expertise, collaborating with leading pharmaceutical and biotechnology companies. It offers a range of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system and a dual-plasmid system for AAV production. The company is headquartered in Oxford, UK, with facilities in the UK, France, and the US.
Average Trading Volume: 147,657
Technical Sentiment Signal: Hold
Current Market Cap: £470.5M
Learn more about OXB stock on TipRanks’ Stock Analysis page.